Dr. Ingbar received his MD from Harvard Medical School and was an Internal Medicine Resident and Chief Resident at the University of Washington before completing his Pulmonary and Critical Care fellowship at Yale University. He is a physician-scientist and was Assistant Professor of Medicine of Cell Biology at Yale before being recruited to the University of Minnesota in 1991. He served for more than 20 years as Director of the Pulmonary, Allergy, Critical Care & Sleep Division in the Department of Medicine and is a Past President of the American Thoracic Society and the Association of Pulmonary & Critical Care Medicine Program Directors. He has served on the ABIM Pulmonary Board and NHLBI Council and is currently on the NCATS national CTSI Steering Committee. Since stepping down as Division Director in 2022, he serves as Assistant Dean for Faculty Development & Mentoring. He co-founded with Marshall Hertz, MD and continues to lead the Center for Lung Science & Health.
His research focuses on understanding how the lung is repaired after injury and how this compares to lung development. He helped understand the regulation of alveolar epithelial ion transport to repair the lung barrier and clear edema fluid, examining the impact of injury and strategies to stimulate fluid clearance. These studies have ranged from morphology to molecular and cell biology to animal model systems. He was both a project and core leader on the NHLBI-funded Specialized Center of Research in ARDS for 10 years. Based on his research, UMN patented a novel first-to-human therapy with a novel thyroid hormone formulation that has been tested in a Phase 1/2A randomized trial for ARDS with no adverse effects and early signs of efficacy. Additional therapeutics with aerosolized and pro-drug therapies are in development in collaboration with the UMN Center for Translational Medicine and with external grant and philanthropic support. These agents will allow treatment of non-intubated patients with ARDS, heart failure, and other inflammatory lung diseases, and for Infant Respiratory Distress Syndrome of prematurity. He has broad experience in translational science that has expanded to include clinical trials, drug development, intellectual property, regulatory issues, and commercialization. He serves as Chief Scientific Officer and a co-founder of Herald Therapeutics - a UMN spin-off start-up company.
A major component of Dr. Ingbar’s activity is mentoring and training of physicians and other translational scientists. He has mentored or co-mentored more than 6 NIH K awardees and many other trainees. For more than 20 years, he was PI of the UMN PACCS Lung Biology T32 (supporting MD and PhD postdoctoral fellows and graduate students), now assisting Chris Wendt, MD, in her leadership role as the T32 corresponding MPI. He is the Principal Investigator of the UMN CTSI K Program, now in its 12th year.
Dr. Ingbar’s inpatient clinical interests are primarily focused on Respiratory Failure, Pulmonary Edema, and ARDS, with additional interest in hemoptysis and pulmonary embolism. He has co-authored the Cardiogenic Shock and Pulmonary Edema chapter in Harrison’s Textbook of Internal Medicine for many editions, co-edited a book on Pulmonary Edema and issues of Clinics in Pulmonary Medicine, and authored or co-authored the UpToDate sections on hemoptysis for many years
Specialty
Pulmonary Physiology - IBP
